(Q34257596)

31 July 2017

Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs (English)

1 reference

31 July 2017

0 references

Ashley Brown

1

1 reference

PubMed ID

22375524

31 July 2017

Zachary Goodman

series ordinal

2

1 reference

31 July 2017

1 April 2012

1 reference

Expert Review of Gastroenterology & Hepatology

31 July 2017

1 reference

31 July 2017

6

1 reference

31 July 2017

2

1 reference

31 July 2017

187-198

1 reference

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

31 July 2017

1 reference

Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update

21 January 2018

1 reference

Chronic hepatitis B: update 2009

21 January 2018

1 reference

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

21 January 2018

1 reference

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

21 January 2018

1 reference

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

21 January 2018

1 reference

High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection

21 January 2018

1 reference

Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

21 January 2018

1 reference

The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B.

21 January 2018

1 reference

Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature

21 January 2018

1 reference

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

Liver fibrosis -- from bench to bedside

21 January 2018

1 reference

Mechanisms of hepatic fibrogenesis

21 January 2018

1 reference

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

Grading and staging systems for inflammation and fibrosis in chronic liver diseases

21 January 2018

1 reference

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

21 January 2018

1 reference

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient.

21 January 2018

1 reference

Progression of fibrosis in advanced chronic hepatitis C: evaluation by morphometric image analysis

21 January 2018

1 reference

Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection

21 January 2018

1 reference

Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation

21 January 2018

1 reference

Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C.

21 January 2018

1 reference

Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss

21 January 2018

1 reference

Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases.

21 January 2018

1 reference

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

21 January 2018

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

21 January 2018

1 reference

Histological outcome during long-term lamivudine therapy.

21 January 2018

1 reference

Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

21 January 2018

1 reference

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

21 January 2018

1 reference

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

21 January 2018

1 reference

Telbivudine versus lamivudine in patients with chronic hepatitis B

21 January 2018

1 reference

2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.

21 January 2018

1 reference

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

21 January 2018

1 reference

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine

21 January 2018

1 reference

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study.

21 January 2018

1 reference

Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B.

21 January 2018

1 reference

Long-term use of entecavir in nucleoside-naïve Japanese patients with chronic hepatitis B infection

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate use.

21 January 2018

1 reference

Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C.

21 January 2018

1 reference

Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.

21 January 2018

1 reference

Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/EGH.12.4

1 reference

31 July 2017

1 reference

PubMed ID

22375524